Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (2770)	2/1/2001 5:29:06 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Thanks, Nigel. I think the appropriate disclaimer is You might well think that. I couldn't possibly comment! <g> (Francis Urquhart in "House of Cards") Peter

To: nigel bates who wrote (2770)	2/1/2001 10:15:42 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 52153

Thanks Nigel, as most suspected, the linkage continues. Curagen does not list investment backers on their releases, except for a small time 15m placement. But << J.P. Morgan & Co. is acting as lead manager for the offering. Goldman, Sachs & Co., Merrill Lynch & Co., Warburg Dillon Read LLC, Lehman Brothers, Inc., and Robertson Stephens are co-managers.>> from th Genentech site, and from Tularik << Tularik Inc. Files Registration Statement For Initial Public Offering Of Common Stock South San Francisco, Calif. October 15, 1999 -- Tularik Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of 6,250,000 shares of common stock. The offering is being made through an underwriter group managed by Lehman Brothers Inc., Hambrecht & Quist LLC, J.P. Morgan & Co. and Warburg Dillon Read LLC. >> Not only does this have a little "conflict of interest oder" but is this not a hint of extorsion - use us or it will go worse for you? Would an SEC complaint have any slight chance of making a difference? Not that I need more stuff to do. Back to some serious, non-investment analysis. Scott